Blog

Latest articles from spravato.clinic

• What Is Spravato? An Evidence-Based Overview for 2026

  May 30, 2026

  Spravato (esketamine) is the first FDA-approved nasal spray for treatment-resistant depression. Here's what patients and families need to know in 2026.

• Spravato vs IV Ketamine: How Clinicians Decide

  May 29, 2026

  Both Spravato and IV ketamine are used for treatment-resistant depression, but they differ in approval status, setting, and clinical fit. Here's how decisions get made.

• Spravato Insurance Coverage in 2026: What Has Changed

  May 28, 2026

  Insurance coverage for Spravato has evolved since its 2019 approval. Here's where things stand in 2026, including Medicare, commercial plans, and prior authorization realities.